You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.

Linaclotide Delayed Release-2

Currently in Phase II Clinical Development

Area of focus:

Non-Constipation GI Disorders Associated with Abdominal Pain
Millions of people in the U.S. suffer from GI disorders associated with abdominal pain but not constipation, including subtypes of IBS, such as IBS with diarrhea (IBS-D) and IBS-Mixed (IBS-M), as well as ulcerative colitis and diverticulitis. It is estimated that 10 million people suffer from IBS-D and 15 million people suffer from IBS-M in the U.S.1,2

Our candidate:

Linaclotide delayed release-2 (DR2) is an investigational medicine being studied to determine whether it can provide delivery of linaclotide to the colon, and it may be evaluated to determine its effect on abdominal pain associated with the specific GI disorders listed above, without producing significant fluid secretion. DR2 is being co-developed by Ironwood Pharmaceuticals and Allergan plc.

« Back to Pipeline


1) Saito, Y., “The epidemiology of irritable bowel syndrome in North America: a systemic review,” Am. J. of Gastroenterology, 2002; 2) Su, A., et al., “Characterizations of irritable bowel syndrome with mixed bowel habit pattern,” Neurogastroenterol Motil., 2014